Anca Leibovici1, Rivka Sharon2, David Azoulay2. 1. Department of Oncology, Galilee Medical Center, Nahariya, Israel, affiliated with Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel. 2. Department of Hematology, Galilee Medical Center, Nahariya, Israel, affiliated with Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel.
Abstract
BACKGROUND: Brain-derived neurotrophic factor (BDNF) is a neuronal growth factor that is important for the development, maintenance, and repair of the peripheral nervous system. The BDNF gene commonly carries a single nucleotide polymorphism (Val66Met-SNP), which affects the cellular distribution and activity-dependent secretion of BDNF in neuronal cells. OBJECTIVES: To check the association between BDNF Val66Met-SNP as a predisposition that enhances the development of chemotherapy-induced peripheral neuropathy in an Israeli cohort of patients with breast cancer who were treated with paclitaxel. METHODS: Peripheral neuropathy symptoms were assessed and graded at baseline, before beginning treatment, and during the treatment protocol in 35 patients, using the reduced version of the Total Neuropathy Score (TNSr). Allelic discrimination of BDNF polymorphism was determined in the patients' peripheral blood by established polymerase chain reaction and Sanger sequencing. RESULTS: We found Val/Val in 20 patients (57.14%), Val/Met in 15 patients (42.86%), and Met/Met in none of the patients (0%). Baseline TNSr scores were higher in Met-BDNF patients compared to Val-BDNF patients. The maximal TNSr scores that developed during the follow-up in Met-BDNF patients were higher than in Val-BDNF patients. However, exclusion of patients with pre-existing peripheral neuropathy from the analysis resulted in equivalent maximal TNSr scores in Met-BDNF and Val-BDNF patients. CONCLUSIONS: These observations suggest that BDNF Val66met-SNP has no detectable effect on the peripheral neuropathy that is induced by paclitaxel. The significance of BDNF Val66Met-SNP in pre-existing peripheral neuropathy-related conditions, such as diabetes, should be further investigated.
BACKGROUND:Brain-derived neurotrophic factor (BDNF) is a neuronal growth factor that is important for the development, maintenance, and repair of the peripheral nervous system. The BDNF gene commonly carries a single nucleotide polymorphism (Val66Met-SNP), which affects the cellular distribution and activity-dependent secretion of BDNF in neuronal cells. OBJECTIVES: To check the association between BDNFVal66Met-SNP as a predisposition that enhances the development of chemotherapy-induced peripheral neuropathy in an Israeli cohort of patients with breast cancer who were treated with paclitaxel. METHODS:Peripheral neuropathy symptoms were assessed and graded at baseline, before beginning treatment, and during the treatment protocol in 35 patients, using the reduced version of the Total Neuropathy Score (TNSr). Allelic discrimination of BDNF polymorphism was determined in the patients' peripheral blood by established polymerase chain reaction and Sanger sequencing. RESULTS: We found Val/Val in 20 patients (57.14%), Val/Met in 15 patients (42.86%), and Met/Met in none of the patients (0%). Baseline TNSr scores were higher in Met-BDNFpatients compared to Val-BDNFpatients. The maximal TNSr scores that developed during the follow-up in Met-BDNFpatients were higher than in Val-BDNFpatients. However, exclusion of patients with pre-existing peripheral neuropathy from the analysis resulted in equivalent maximal TNSr scores in Met-BDNF and Val-BDNFpatients. CONCLUSIONS: These observations suggest that BDNFVal66met-SNP has no detectable effect on the peripheral neuropathy that is induced by paclitaxel. The significance of BDNFVal66Met-SNP in pre-existing peripheral neuropathy-related conditions, such as diabetes, should be further investigated.
Authors: Alberto Guijosa; Ana Freyria; Jose Rodrigo Espinosa-Fernandez; Francisco J Estrada-Mena; Ana Sofía Armenta-Quiroga; Maria Fernanda Ortega-Treviño; Rodrigo Catalán; Bani Antonio-Aguirre; Cynthia Villarreal-Garza; Andric C Perez-Ortiz Journal: Clin Transl Sci Date: 2022-08-17 Impact factor: 4.438
Authors: Anukriti Sharma; Ken B Johnson; Bihua Bie; Emily E Rhoades; Alper Sen; Yuri Kida; Jennifer Hockings; Alycia Gatta; Jacqueline Davenport; Connie Arcangelini; Jennifer Ritzu; Jennifer DeVecchio; Ron Hughen; Mei Wei; G Thomas Budd; N Lynn Henry; Charis Eng; Joseph Foss; Daniel M Rotroff Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec